Adherence to preventive medications: Predictors and outcomes in the diabetes prevention program

Elizabeth A. Walker, Mark Molitch, M. Kaye Kramer, Steven Kahn, Yong Ma, Sharon Edelstein, Kellie Smith, Mariana Kiefer Johnson, Abbas Kitabchi, Jill P. Crandall

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

OBJECTIVE - To evaluate barriers to and strategies for medication adherence and predictors of adherence and the primary outcome in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS - Within a randomized, controlled primary prevention study for type 2 diabetes, we collected data on study medication adherence, its predictors, and health outcomes in 27 clinical centers across mainland U.S. and Hawaii. Medication arm participants included 2,155 adults with impaired glucose tolerance randomly assigned to either metformin or matched placebo treatment arms. Structured interviews were used to promote medication adherence and to collect data regarding adherence. Adherence was measured by pill count. The primary DPP outcome of type 2 diabetes was assessed by fasting plasma glucose and oral glucose tolerance test. RESULTS - Older age-groups were more adherent than the youngest group (P = 0.01) in the metformin group. The most frequently reported barrier to adherence was "forgetting" (22%). Women reported more adverse effects of metformin (15 vs. 10%, P = 0.002) in the metformin group. Odds of nonadherence increased as participants reported more than one barrier (odds ratio 19.1, P < 0.001). Odds of adherence increased as participants reported multiple strategies to take medication (2.69, P < 0.0001). There was a 38.2% risk reduction for developing diabetes for those adherent to metformin compared with those adherent to placebo (P < 0.0003). CONCLUSIONS - DPP medication adherence results are unique in primary prevention for a chronic disease in a large multiethnic sample. Our finding that adherence was associated with risk reduction for diabetes supports the development of brief interventions in clinical settings where medication adherence is a challenge.

Original languageEnglish (US)
Pages (from-to)1997-2002
Number of pages6
JournalDiabetes Care
Volume29
Issue number9
DOIs
StatePublished - 2006

Fingerprint

Medication Adherence
Metformin
Primary Prevention
Risk Reduction Behavior
Type 2 Diabetes Mellitus
Placebos
Glucose Intolerance
Glucose Tolerance Test
Fasting
Chronic Disease
Research Design
Age Groups
Odds Ratio
Interviews
Glucose
Health

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Adherence to preventive medications : Predictors and outcomes in the diabetes prevention program. / Walker, Elizabeth A.; Molitch, Mark; Kramer, M. Kaye; Kahn, Steven; Ma, Yong; Edelstein, Sharon; Smith, Kellie; Johnson, Mariana Kiefer; Kitabchi, Abbas; Crandall, Jill P.

In: Diabetes Care, Vol. 29, No. 9, 2006, p. 1997-2002.

Research output: Contribution to journalArticle

Walker, EA, Molitch, M, Kramer, MK, Kahn, S, Ma, Y, Edelstein, S, Smith, K, Johnson, MK, Kitabchi, A & Crandall, JP 2006, 'Adherence to preventive medications: Predictors and outcomes in the diabetes prevention program', Diabetes Care, vol. 29, no. 9, pp. 1997-2002. https://doi.org/10.2337/dc06-0454
Walker, Elizabeth A. ; Molitch, Mark ; Kramer, M. Kaye ; Kahn, Steven ; Ma, Yong ; Edelstein, Sharon ; Smith, Kellie ; Johnson, Mariana Kiefer ; Kitabchi, Abbas ; Crandall, Jill P. / Adherence to preventive medications : Predictors and outcomes in the diabetes prevention program. In: Diabetes Care. 2006 ; Vol. 29, No. 9. pp. 1997-2002.
@article{39437034beac4b4cb0bb5e93e271e85b,
title = "Adherence to preventive medications: Predictors and outcomes in the diabetes prevention program",
abstract = "OBJECTIVE - To evaluate barriers to and strategies for medication adherence and predictors of adherence and the primary outcome in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS - Within a randomized, controlled primary prevention study for type 2 diabetes, we collected data on study medication adherence, its predictors, and health outcomes in 27 clinical centers across mainland U.S. and Hawaii. Medication arm participants included 2,155 adults with impaired glucose tolerance randomly assigned to either metformin or matched placebo treatment arms. Structured interviews were used to promote medication adherence and to collect data regarding adherence. Adherence was measured by pill count. The primary DPP outcome of type 2 diabetes was assessed by fasting plasma glucose and oral glucose tolerance test. RESULTS - Older age-groups were more adherent than the youngest group (P = 0.01) in the metformin group. The most frequently reported barrier to adherence was {"}forgetting{"} (22{\%}). Women reported more adverse effects of metformin (15 vs. 10{\%}, P = 0.002) in the metformin group. Odds of nonadherence increased as participants reported more than one barrier (odds ratio 19.1, P < 0.001). Odds of adherence increased as participants reported multiple strategies to take medication (2.69, P < 0.0001). There was a 38.2{\%} risk reduction for developing diabetes for those adherent to metformin compared with those adherent to placebo (P < 0.0003). CONCLUSIONS - DPP medication adherence results are unique in primary prevention for a chronic disease in a large multiethnic sample. Our finding that adherence was associated with risk reduction for diabetes supports the development of brief interventions in clinical settings where medication adherence is a challenge.",
author = "Walker, {Elizabeth A.} and Mark Molitch and Kramer, {M. Kaye} and Steven Kahn and Yong Ma and Sharon Edelstein and Kellie Smith and Johnson, {Mariana Kiefer} and Abbas Kitabchi and Crandall, {Jill P.}",
year = "2006",
doi = "10.2337/dc06-0454",
language = "English (US)",
volume = "29",
pages = "1997--2002",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Adherence to preventive medications

T2 - Predictors and outcomes in the diabetes prevention program

AU - Walker, Elizabeth A.

AU - Molitch, Mark

AU - Kramer, M. Kaye

AU - Kahn, Steven

AU - Ma, Yong

AU - Edelstein, Sharon

AU - Smith, Kellie

AU - Johnson, Mariana Kiefer

AU - Kitabchi, Abbas

AU - Crandall, Jill P.

PY - 2006

Y1 - 2006

N2 - OBJECTIVE - To evaluate barriers to and strategies for medication adherence and predictors of adherence and the primary outcome in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS - Within a randomized, controlled primary prevention study for type 2 diabetes, we collected data on study medication adherence, its predictors, and health outcomes in 27 clinical centers across mainland U.S. and Hawaii. Medication arm participants included 2,155 adults with impaired glucose tolerance randomly assigned to either metformin or matched placebo treatment arms. Structured interviews were used to promote medication adherence and to collect data regarding adherence. Adherence was measured by pill count. The primary DPP outcome of type 2 diabetes was assessed by fasting plasma glucose and oral glucose tolerance test. RESULTS - Older age-groups were more adherent than the youngest group (P = 0.01) in the metformin group. The most frequently reported barrier to adherence was "forgetting" (22%). Women reported more adverse effects of metformin (15 vs. 10%, P = 0.002) in the metformin group. Odds of nonadherence increased as participants reported more than one barrier (odds ratio 19.1, P < 0.001). Odds of adherence increased as participants reported multiple strategies to take medication (2.69, P < 0.0001). There was a 38.2% risk reduction for developing diabetes for those adherent to metformin compared with those adherent to placebo (P < 0.0003). CONCLUSIONS - DPP medication adherence results are unique in primary prevention for a chronic disease in a large multiethnic sample. Our finding that adherence was associated with risk reduction for diabetes supports the development of brief interventions in clinical settings where medication adherence is a challenge.

AB - OBJECTIVE - To evaluate barriers to and strategies for medication adherence and predictors of adherence and the primary outcome in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS - Within a randomized, controlled primary prevention study for type 2 diabetes, we collected data on study medication adherence, its predictors, and health outcomes in 27 clinical centers across mainland U.S. and Hawaii. Medication arm participants included 2,155 adults with impaired glucose tolerance randomly assigned to either metformin or matched placebo treatment arms. Structured interviews were used to promote medication adherence and to collect data regarding adherence. Adherence was measured by pill count. The primary DPP outcome of type 2 diabetes was assessed by fasting plasma glucose and oral glucose tolerance test. RESULTS - Older age-groups were more adherent than the youngest group (P = 0.01) in the metformin group. The most frequently reported barrier to adherence was "forgetting" (22%). Women reported more adverse effects of metformin (15 vs. 10%, P = 0.002) in the metformin group. Odds of nonadherence increased as participants reported more than one barrier (odds ratio 19.1, P < 0.001). Odds of adherence increased as participants reported multiple strategies to take medication (2.69, P < 0.0001). There was a 38.2% risk reduction for developing diabetes for those adherent to metformin compared with those adherent to placebo (P < 0.0003). CONCLUSIONS - DPP medication adherence results are unique in primary prevention for a chronic disease in a large multiethnic sample. Our finding that adherence was associated with risk reduction for diabetes supports the development of brief interventions in clinical settings where medication adherence is a challenge.

UR - http://www.scopus.com/inward/record.url?scp=33845346826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845346826&partnerID=8YFLogxK

U2 - 10.2337/dc06-0454

DO - 10.2337/dc06-0454

M3 - Article

C2 - 16936143

AN - SCOPUS:33845346826

VL - 29

SP - 1997

EP - 2002

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -